{
  "abstract": "Background. The LENAddOn study aimed to characterize people with HIV (PWH) initiating injectable lenacapavir (LEN) post-early access program in France, assess LEN continuation rates at W26 and W52, and describe reasons for LEN discontinuation.\n\nMethods. Observational, retrospective study across 19 centers, including people with HIV-1 who initiated LEN between 20 June 2023 and 30 June 2024. Sociodemographic, clinical, and laboratory data were extracted from medical records. The primary outcome was the proportion of PWH receiving a second and third set of LEN injections at W26 and W52.\n\nResults. Seventy-seven PWH were included (median age, 57 years [IQR, 44-63]; duration of antiretroviral therapy (ART), 25 years [17-29]), with a history of frequent adherence issues and vulnerability factors. At LEN initiation, 22 (28.6%) had a plasma HIV-1 viral load (pVL) ≥200 copies/mL, and 43 (55.8%) had a pVL <50 copies/mL; 42 (54.6%) had viral resistance to ≥2 drugs in ≥3 classes. Twenty-one participants (27.3%) received injectable ART associating LEN plus cabotegravir ± rilpivirine. Lenacapavir continuation rate was 94.8% (95% CI, 87.2-98.6) at W26 and 81.8% (71.4-89.7) at W52, with 4 LEN discontinuations between D0 and W26 and 10 between W26 and W52. Main reasons for LEN discontinuation were death unrelated to LEN/lost-to-follow-up (n = 5), persistence of viral replication (n = 3), and injection site reactions (n = 2). Last measured pVL during the study period was <200 cp/mL in 72/77 participants (93.5%) and <50 cp/mL in 61/77 (79.2%).\n\nConclusions. Lenacapavir use allowed simplification of antiretroviral regimens, with the maintenance or achievement of virological suppression. Continuation of LEN at W26 and W52 remained high among a population with extensive treatment history.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 77,
  "authors": [
    {
      "name": "Jade Ghosn"
    },
    {
      "name": "Valérie Pourcher"
    },
    {
      "name": "Clotilde Allavena"
    },
    {
      "name": "Laurent Hocqueloux"
    },
    {
      "name": "Karine Lacombe"
    },
    {
      "name": "Eric Cua"
    },
    {
      "name": "Fabrice Bonnet"
    },
    {
      "name": "Claudine Duvivier"
    },
    {
      "name": "Alain Makinson"
    },
    {
      "name": "Christine Jacomet"
    },
    {
      "name": "Caroline Lascoux"
    },
    {
      "name": "Jean-Paul Viard"
    },
    {
      "name": "Olivier Robineau"
    },
    {
      "name": "Maxime Hentzien"
    },
    {
      "name": "Elina Teicher"
    },
    {
      "name": "Gilles Pialoux"
    },
    {
      "name": "Sophie Abgrall"
    },
    {
      "name": "Charles Cazanave"
    },
    {
      "name": "André Cabié"
    },
    {
      "name": "Yasmine Dudoit"
    },
    {
      "name": "Gilles Peytavin"
    },
    {
      "name": "Guillaume Barrière"
    },
    {
      "name": "Keith Dunn"
    },
    {
      "name": "Anne-Geneviève Marcelin"
    },
    {
      "name": "Lambert Assoumou"
    },
    {
      "name": "Pauline Perreau"
    },
    {
      "name": "Tanguy Vincent"
    },
    {
      "name": "Jean Delaune"
    },
    {
      "name": "Camille Krzyzanowsky"
    },
    {
      "name": "Agnès Cros"
    },
    {
      "name": "Laurent Richier"
    },
    {
      "name": "Corinne Merle"
    },
    {
      "name": "Célia Bouhnik"
    },
    {
      "name": "Barbara de Dieuleveult"
    },
    {
      "name": "Cécile Goujard"
    },
    {
      "name": "Yann Quertainmont"
    },
    {
      "name": "Sandrine Poirier"
    },
    {
      "name": "Véronique Godard"
    },
    {
      "name": "Caroline Proux"
    },
    {
      "name": "Antoine Bachelard"
    },
    {
      "name": "Zélie Julia"
    },
    {
      "name": "Racha Ibrahim"
    },
    {
      "name": "Awa Ndiaye"
    },
    {
      "name": "Ornella Cabras"
    },
    {
      "name": "Lorry Facelina"
    },
    {
      "name": "Firouzé Bani-Sadr"
    },
    {
      "name": "Yohan Nguyen"
    },
    {
      "name": "Isabelle Kmiec"
    },
    {
      "name": "Wiem Loghmari"
    },
    {
      "name": "Valérie Le Baut"
    },
    {
      "name": "Morane Cavallec"
    },
    {
      "name": "Soria Albane"
    },
    {
      "name": "Ernesto Paredes Manyari"
    },
    {
      "name": "Sophie Breaud"
    },
    {
      "name": "Iris Touitou"
    },
    {
      "name": "Martin Siguier"
    },
    {
      "name": "Christia Palacios"
    },
    {
      "name": "Mouniya Mebarki"
    },
    {
      "name": "Anne Adda-Lievin"
    },
    {
      "name": "Dilek Coban"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5ba2pazr70cfq.bib",
  "cited_by": 0,
  "doi": "10.1093/ofid/ofag512",
  "fulltext_url": null,
  "id": "5ba2pazr70cfq",
  "issns": [
    "2328-8957",
    "2328-8957"
  ],
  "landing_url": "https://u-bordeaux.hal.science/hal-05744307v1",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.spee"
    ],
    [
      "openalex",
      "2725|HIV/AIDS drug development and treatment"
    ]
  ],
  "openalex": "W7203792536",
  "pdf_url": "https://u-bordeaux.hal.science/hal-05744307/document",
  "pmcid": null,
  "pmid": "42639442",
  "published": "2026-08-19",
  "publisher": "Oxford University Press",
  "ris": "https://research.draconitic.com/paper/5ba2pazr70cfq.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:33Z",
      "native_id": "hal-05744307",
      "source": "hal",
      "url": "https://u-bordeaux.hal.science/hal-05744307v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:0.sdv",
      "subfield": "general"
    },
    {
      "field": "medicine",
      "origin": "hal:1.sdv.spee",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Lenacapavir Use in France: A National, Observational Study (LENAddOn)",
  "title_text": "Lenacapavir Use in France: A National, Observational Study (LENAddOn)",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:33Z",
  "url": "https://research.draconitic.com/paper/5ba2pazr70cfq",
  "venue": "Open Forum Infectious Diseases",
  "versions": []
}